The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

卷:84

Article

Durgin, Joseph S.¹  Weiner, David M.¹  Wysocka, Maria¹  Rook, Alain H.¹ 

[1] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA

关键词: CTCL;    cutaneous T cell lymphoma;    dermatologic oncology;    drug response;    immune deficiency;    immunopathogenesis;    immunotherapy;    mycosis fungoides;    Sezary syndrome;   

DOI  :  10.1016/j.jaad.2020.12.027

来源: Elsevier

【 摘 要 】

Cutaneous T cell lymphomas (CTCLs) are malignancies of skin-trafficking T cells. Patients with advanced CTCL manifest immune dysfunction that predisposes to infection and suppresses the antitumor immune response. Therapies that stimulate immunity have produced superior progression-free survival compared with conventional chemotherapy, reinforcing the importance of addressing the immune deficient state in the care of patients with CTCL. Recent research has better defined the pathogenesis of these immune deficits, explaining the mechanisms of disease progression and revealing potential therapeutic targets. The features of the malignant cell in mycosis fungoides and Sezary syndrome are now significantly better understood, including the T helper 2 cell phenotype, regulatory T cell cytokine production, immune checkpoint molecule expression, chemokine receptors, and interactions with the microenvironment. The updated model of CTCL immunopathogenesis provides understanding into clinical progression and therapeutic response.

【 授权许可】

Free